A self-assembling short oligonucleotide duplex suitable for pretargeting

Prabodhika Mallikaratchy, Jeffery Gardner, Larsulrik R. Nordstroem, Nicholas J. Veomett, Michael R. McDevitt, Mark L. Heaney, David A. Scheinberg

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties. A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears a cognate receptor for the mAb. Here, we introduce a novel pretargetable RNA based system comprised of locked nucleic acids (LNA) and 2′O-Methyloligoribonucleotides (2′OMe-RNA). The duplex shows fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability in plasma. Using a prototype model system with rituximab conjugated to 2′OMe-RNA (oligo), we demonstrate that LNA-based complementary strand (c-oligo) effectively hybridizes with rituximab-oligo, which is slowly circulating in vivo, despite the high clearance rates of c-oligo.

Original languageEnglish (US)
Pages (from-to)289-299
Number of pages11
JournalNucleic Acid Therapeutics
Volume23
Issue number4
DOIs
StatePublished - Aug 1 2013
Externally publishedYes

Fingerprint

Oligonucleotides
RNA
Monoclonal Antibodies
Molecules
Pharmacokinetics
Freezing
Melting point
Ligands
Plasmas
Imaging techniques
Temperature
locked nucleic acid
Rituximab

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Biochemistry
  • Drug Discovery

Cite this

Mallikaratchy, P., Gardner, J., Nordstroem, L. R., Veomett, N. J., McDevitt, M. R., Heaney, M. L., & Scheinberg, D. A. (2013). A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Therapeutics, 23(4), 289-299. https://doi.org/10.1089/nat.2013.0425

A self-assembling short oligonucleotide duplex suitable for pretargeting. / Mallikaratchy, Prabodhika; Gardner, Jeffery; Nordstroem, Larsulrik R.; Veomett, Nicholas J.; McDevitt, Michael R.; Heaney, Mark L.; Scheinberg, David A.

In: Nucleic Acid Therapeutics, Vol. 23, No. 4, 01.08.2013, p. 289-299.

Research output: Contribution to journalArticle

Mallikaratchy, P, Gardner, J, Nordstroem, LR, Veomett, NJ, McDevitt, MR, Heaney, ML & Scheinberg, DA 2013, 'A self-assembling short oligonucleotide duplex suitable for pretargeting', Nucleic Acid Therapeutics, vol. 23, no. 4, pp. 289-299. https://doi.org/10.1089/nat.2013.0425
Mallikaratchy P, Gardner J, Nordstroem LR, Veomett NJ, McDevitt MR, Heaney ML et al. A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Therapeutics. 2013 Aug 1;23(4):289-299. https://doi.org/10.1089/nat.2013.0425
Mallikaratchy, Prabodhika ; Gardner, Jeffery ; Nordstroem, Larsulrik R. ; Veomett, Nicholas J. ; McDevitt, Michael R. ; Heaney, Mark L. ; Scheinberg, David A. / A self-assembling short oligonucleotide duplex suitable for pretargeting. In: Nucleic Acid Therapeutics. 2013 ; Vol. 23, No. 4. pp. 289-299.
@article{1fd146bff58149a2a640b2277e64a472,
title = "A self-assembling short oligonucleotide duplex suitable for pretargeting",
abstract = "Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties. A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears a cognate receptor for the mAb. Here, we introduce a novel pretargetable RNA based system comprised of locked nucleic acids (LNA) and 2′O-Methyloligoribonucleotides (2′OMe-RNA). The duplex shows fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability in plasma. Using a prototype model system with rituximab conjugated to 2′OMe-RNA (oligo), we demonstrate that LNA-based complementary strand (c-oligo) effectively hybridizes with rituximab-oligo, which is slowly circulating in vivo, despite the high clearance rates of c-oligo.",
author = "Prabodhika Mallikaratchy and Jeffery Gardner and Nordstroem, {Larsulrik R.} and Veomett, {Nicholas J.} and McDevitt, {Michael R.} and Heaney, {Mark L.} and Scheinberg, {David A.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1089/nat.2013.0425",
language = "English (US)",
volume = "23",
pages = "289--299",
journal = "Nucleic Acid Therapeutics",
issn = "2159-3337",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - A self-assembling short oligonucleotide duplex suitable for pretargeting

AU - Mallikaratchy, Prabodhika

AU - Gardner, Jeffery

AU - Nordstroem, Larsulrik R.

AU - Veomett, Nicholas J.

AU - McDevitt, Michael R.

AU - Heaney, Mark L.

AU - Scheinberg, David A.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties. A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears a cognate receptor for the mAb. Here, we introduce a novel pretargetable RNA based system comprised of locked nucleic acids (LNA) and 2′O-Methyloligoribonucleotides (2′OMe-RNA). The duplex shows fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability in plasma. Using a prototype model system with rituximab conjugated to 2′OMe-RNA (oligo), we demonstrate that LNA-based complementary strand (c-oligo) effectively hybridizes with rituximab-oligo, which is slowly circulating in vivo, despite the high clearance rates of c-oligo.

AB - Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties. A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears a cognate receptor for the mAb. Here, we introduce a novel pretargetable RNA based system comprised of locked nucleic acids (LNA) and 2′O-Methyloligoribonucleotides (2′OMe-RNA). The duplex shows fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability in plasma. Using a prototype model system with rituximab conjugated to 2′OMe-RNA (oligo), we demonstrate that LNA-based complementary strand (c-oligo) effectively hybridizes with rituximab-oligo, which is slowly circulating in vivo, despite the high clearance rates of c-oligo.

UR - http://www.scopus.com/inward/record.url?scp=84881175157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881175157&partnerID=8YFLogxK

U2 - 10.1089/nat.2013.0425

DO - 10.1089/nat.2013.0425

M3 - Article

VL - 23

SP - 289

EP - 299

JO - Nucleic Acid Therapeutics

JF - Nucleic Acid Therapeutics

SN - 2159-3337

IS - 4

ER -